Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”

Executive Summary

Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy
Advertisement

Related Content

FDA panel to review Solvay cilansetron
FDA panel to review Solvay cilansetron
Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs
Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs
GSK Lotronex Risk Management Plan Should Not Be Altered, Cmte. Says
Novartis Revises Zelnorm Labeling With Diarrhea, Ischemic Colitis Risk Info
GSK Lotronex Plan Follows Accutane Model; Relaunch “Months” Away
Solvay Cilansetron Irritable Bowel Safety Trial Size Reflects FDA Concerns
Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations
Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations
Advertisement
UsernamePublicRestriction

Register

PS044044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel